TAK1 inhibition for treatment of cerebral ischemia

Dirk A. Ridder, Markus Schwaninger*

*Corresponding author for this work
11 Citations (Scopus)


TGFß-activated kinase 1 (TAK1), a MAP3 kinase, is involved in at least five signaling cascades that modulate ischemic brain damage. Inhibition of TAK1may therefore be an efficient way to interfere with multiple mechanisms in ischemic stroke. Indeed, a recent publication in Experimental Neurology confirmed that TAK1 inhibition by 5Z-7-oxozeaenol is neuroprotective. The beneficial effect of 5Z-7-oxozeaenol was associated with a reduced activation of Jun kinase that leads to inflammation and apoptosis. Recently, other TAK1 inhibitors were developed suggesting that TAK1 may prove as an efficient therapeutic target for neurodegenerative diseases if safety issues are not limiting.

Original languageEnglish
JournalExperimental Neurology
Issue number1
Pages (from-to)68-72
Number of pages5
Publication statusPublished - 01.01.2013


Dive into the research topics of 'TAK1 inhibition for treatment of cerebral ischemia'. Together they form a unique fingerprint.

Cite this